ライフサイエンスコーパス: Takayasu

1 Takayasu arteritis (TAK) is a granulomatous large-vessel

2 Takayasu arteritis (TAK) is a large vessel vasculitis re

3 Takayasu arteritis (TAK) is a rare, chronic, large-vesse

4 Takayasu arteritis is a rare idiopathic large-vessel vas

5 Takayasu arteritis is a rare inflammatory disease of lar

6 Takayasu arteritis is an inflammatory disease of large-d

7 Takayasu arteritis is more frequently seen in younger po

8 Takayasu arteritis occurs mainly in young women and, if

9 Takayasu arteritis was compared to hundreds of other tra

10 Takayasu's arteritis (TAK) is a large-vessel vasculitis

11 lated aortitis, 57 giant cells arteritis, 21 Takayasu arteritis, and 21 with various systemic autoimm

12 ety-five patients (giant cell arteritis, 52; Takayasu arteritis, 43) contributed 212 (18)F-FDG PET st

13 e itself may be accompanied by aortitis or a Takayasu's-like or medium-sized vessel vasculitis.

14 ammatory disorders (giant cell arteritis and Takayasu arteritis) are the most common form of systemic

15 istinct conditions, giant cell arteritis and Takayasu arteritis, although the phenotypic spectrum of

16 es of patients with giant cell arteritis and Takayasu arteritis, and serum levels of this cytokine mi

17 des, including both giant cell arteritis and Takayasu arteritis, and the aortitis of Cogan syndrome a

18 ssel vasculitis are giant cell arteritis and Takayasu arteritis, and those of medium-vessel arteritis

19 et Still's disease, giant cell arteritis and Takayasu arteritis, as well as other conditions such as

20 conditions include giant cell arteritis and Takayasu arteritis, with isolated aortitis being increas

21 of disease in both giant cell arteritis and Takayasu arteritis.

22 ologic and includes giant cell arteritis and Takayasu arteritis.

23 r's granulomatosis, giant cell arteritis and Takayasu's arteritis in the US amounted to $150 million

24 sts: pentraxin-3 in giant cell arteritis and Takayasu's arteritis; von Willebrand factor antigen in c

25 (PET Imaging of Giant Cell and Takayasu Arteritis [PITA], NCT04071691; Residual Inflamm

26 ndylitis, primary sclerosing cholangitis and Takayasu's arteritis(3-6)-we identify that the causal ge

27 litis such as giant cell arteritis (GCA) and Takayasu arteritis (TAK).

28 Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are major forms of large-vess

29 lso called temporal arteritis) is a rare and Takayasu arteritis (TA) is an even rarer autoimmune dise

30 osa, Kawasaki disease, giant cell arteritis, Takayasu arteritis, and Behcet's disease.

31 litis (LVV), including giant cell arteritis, Takayasu's arteritis, immunoglobulin G4-related aortitis

32 Large vessel vasculitides, such as Takayasu arteritis and giant cell arteritis, affect vita

33 rtery inflammatory vascular disease, such as Takayasu arteritis, chemotherapy- or radiation-induced v

34 history of some of these conditions, such as Takayasu arteritis, includes a very long period of low l

35 10(-5)) and devised a genetic risk score for Takayasu arteritis.

36 ar wall and lumen pathologies resulting from Takayasu arteritis.

37 i suggest roles for monocytes and B cells in Takayasu arteritis.

38 irin in the prevention of ischemic events in Takayasu's disease.

39 logically similar to the lesions observed in Takayasu's arteritis, the nongranulomatous variant of te

40 The outlook in Takayasu arteritis has improved over the last decade, re

41 ment using percutaneous intervention (PI) in Takayasu arteritis (TAK) remains unresolved.

42 We performed a genetic study in Takayasu arteritis comprising 6,670 individuals (1,226 a

43 ol for disease assessment include the Indian Takayasu Clinical Activity Score (ITAS2010), which incor

44 ed stenoses of its main branches, indicating Takayasu arteritis.

45 on and may present as transient visual loss, Takayasu retinopathy (TR), or ischemic optic neuropathy.

46 ies may help accurately diagnose and monitor Takayasu arteritis (TAK).

47 cause of the wide variation in the course of Takayasu arteritis (TA), predicting outcome is challengi

48 ent who fulfilled the diagnostic criteria of Takayasu's arteritis and pulmonary hypertension were inc

49 s have evidenced a worldwide distribution of Takayasu arteritis.

50 omatous inflammation is a typical feature of Takayasu arteritis (TA), and tumor necrosis factor (TNF)

51 gate the clinical and laboratory features of Takayasu arteritis (TAK) and explore the risk factors th

52 s considered the gold standard in imaging of Takayasu arteritis.

53 ticularly attractive for arterial lesions of Takayasu arteritis.

54 iew recent advances in medical management of Takayasu arteritis, with a special focus on the rational

55 rgery remains important in the management of Takayasu arteritis.

56 boratory, and radiographic manifestations of Takayasu arteritis (TA) in a cohort from the US, evaluat

57 mproved disease activity in small numbers of Takayasu's patients, including those refractory to anti-

58 of the genetic basis and pathophysiology of Takayasu arteritis and provides clues for potential new

59 t they may be effective for the treatment of Takayasu's arteritis, but their role in the treatment of

60 agents are recommended for the treatment of Takayasu's patients who are unable to taper prednisone d

61 thods: Patients with giant cell arteritis or Takayasu arteritis underwent independent clinical and im

62 rituximab, and some patients with refractory Takayasu arteritis have responded to the immunomodulator

63 pus erythematosus (SLE), systemic sclerosis, Takayasu arteritis, Wegener granulomatosis, Behcet syndr

64 sculopathies, ranging from the vasculitides (Takayasu arteritis, giant cell arteritis, and polyarteri

65 rsons of northern European ancestry, whereas Takayasu arteritis occurs mainly in those aged under 40

66 l 9 patients (2 with Marfan syndrome, 1 with Takayasu's disease) with undiagnosed aortic dissection h

67 acteristics and outcomes of 49 patients with Takayasu arteritis (80% female; median age, 42 years [20

68 and outcomes of 79 consecutive patients with Takayasu arteritis (median age, 39 years; interquartile

69 nce (CMR) in the assessment of patients with Takayasu arteritis (TA).

70 ty in approximately 50% of all patients with Takayasu arteritis (TA).

71 A small number of patients with Takayasu arteritis and IgG4-related aortitis have also b

72 rform successful monitoring of patients with Takayasu arteritis and to plan possible interventional t

73 Eighty-eight percent of patients with Takayasu arteritis were inadequately controlled with or

74 geted treatments in refractory patients with Takayasu arteritis with an acceptable safety profile.

75 ntagonists and tocilizumab) in patients with Takayasu arteritis.

76 ons after revascularization in patients with Takayasu arteritis.

77 long-term survival outcome in patients with Takayasu's arteritis-associated pulmonary hypertension (